1

Paratek Pharmaceuticals, USA

Drug development antibacterials

www.paratekpharma.com

HBM contact: Dr Ivo Staijen, Dr Matthias Fehr

Company status: public

Paratek’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171